Cancer-Associated Thrombosis on Bevacizumab: Risk of Recurrence and Bleeding When Bevacizumab Is Stopped or Continued

Cancer-Associated Thrombosis on Bevacizumab: Risk of Recurrence and Bleeding When Bevacizumab Is Stopped or Continued

Cancer-associated thrombosis (CAT) is a common complication during cancer, with complex management due to an increased risk of both recurrence and bleeding. Bevacizumab is an effective anti-angiogenic treatment but increases the risk of bleeding and potentially the risk of venous thromboembolism (VT...

Full description

Bibliographic Details
Main Authors: Marie Mayenga, Nicolas Falvo, Isabelle Mahé, Anne-Sophie Jannot, Benoit Gazeau, Guy Meyer, Nicolas Gendron, Olivier Sanchez, Sadji Djennaoui, Benjamin Planquette
Format: Article
Language:English
Published: MDPI AG 2023-07-01
Series:Cancers
Subjects:
anti-angiogenic drug
anticoagulant
bevacizumab
bleeding
cancer
recurrence
Online Access:https://www.mdpi.com/2072-6694/15/15/3893

Internet

https://www.mdpi.com/2072-6694/15/15/3893

Similar Items